ODAC cleared efficacy. The Crl led to a Bla on Msb's terms so Fda are obviously open to considering it adequate rather than holding firm on the requirement for another trial. Dangerous assumptions at a 800m market cap. If we partner up, cashflow no longer becomes a concern even if another trial is required and we cruise into heart and back. How much would a big pharma have to pay to get in this late?
Ann: MSB Reports Q3 Financial Results and Operational Highlights, page-320
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.015(1.49%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 94.0¢ | $11.76M | 11.90M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 206912 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 37637 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |